Active vs Passive Funds: Relative performance over the past decade

Why active fund management continues to create value in India’s equity markets | Published: 18-Feb-25

Active vs Passive Funds: Relative performance over the past decade

Passive investing works well in highly efficient markets—but India is different.

This data-backed whitepaper examines a decade of performance across mutual funds and PMS strategies to show where and why active managers in India have been able to consistently outperform passive benchmarks.

Download Now

Globally, the rise of passive investing has been driven by the belief that markets are efficient and that low-cost index funds deliver superior long-term outcomes. While this argument often holds in highly institutionalised markets such as the U.S., it does not translate cleanly to India’s equity markets.

This whitepaper examines why India remains structurally favourable for active fund management. With lower institutional participation, a higher share of retail flows, and persistent inefficiencies across market segments, Indian equities continue to offer skilled managers the opportunity to generate alpha through research, stock selection, and tactical allocation.

Using publicly available performance data from 2015 to 2024, the study analyses mutual funds and PMS strategies across Large Cap, Large & Mid Cap, Flexi Cap, Mid Cap, and Small Cap categories. The findings show that active funds have not only outperformed their benchmarks in a majority of cases, but have done so consistently across different market cycles—including both strong bull phases and periods of stress.

Importantly, the results are broad-based. Outperformance is not limited to a small group of star managers. Even at the average fund level, active strategies have delivered meaningful excess returns over passive benchmarks, translating into significant real-world wealth differences over long investment horizons.

The whitepaper also highlights the few periods where passive strategies temporarily performed better, explaining why such phases tend to be cyclical rather than structural. For investors, the takeaway is clear: in India, active investing remains a powerful long-term tool—but outcomes depend heavily on fund selection, discipline, and the quality of research underpinning portfolio decisions.

Experience the benefits of working with a 'research-first' investments firm

Free 15-Day Trial of IME RMS App

Enjoy a complimentary 15-day trial of IME RMS and 3 1-hour consultations with a Senior Private Banker.

Access IME’s central research insights across MFs, PMSs, AIFs, SIFs and global funds, along with personalised support on risk profiling, mandate design, financial planning, and a portfolio review.

Experience the difference a research-first, transparent approach can make to your wealth journey.

IME RMS Demo

IME Capital Logo

IME Capital is a research-first investments firm. We aim to disrupt the wealth management industry, by shrinking the gap in investment insights between central research teams & RMs/Clients.

Disclaimer MF/PMS/AIF/Direct Equities are all subject to market risks. Please read the scheme information and other related documents carefully prior to investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund or designing a portfolio that suits your needs. Market & other data on this site has been sourced from what are considered to be reliable sources. All views shared (product ratings, views on individual securities etc.) are the proprietary property of IME Capital and cannot be used in any form without explicit written consent. IME Capital Pvt. Ltd. makes no warranties or representations, express or implied, on products offered through the platform (and that of our partners) or on the correctness of data & views shared. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Detailed Disclaimer | © 2021 All rights reserved | ARN No: ARN-182445